Table 1. Clinical characteristics of the endometrial cancer patients and circulating tumor DNA detection.
| Patient | Histology | FIGO Stage | Grade | Myometrial invasion (%) | Lymph-Vascular Space Invasion | Lymph Node Status | SLN vs. LND (N of nodes) | Omental / Peritoneal disease | CA125 pre-Surgery | Adjuvant treatment | Time of FUP (months) | Vital status | Time (months) to Relapse (R) or Progressive Disease (PD) | Sites of Relapse or Progressive Disease |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTE006 | Endom | IA | 3 | 23% | Yes | Neg | SLN (4) | No | 50 | VRT | 44 | AWD | 32 (R) | Peritoneum; Liver |
| CTE034 | Endom | IA | 3 | 29% | No | Neg | SLN (4) | No | 29 | VRT | 25 | NED | / | / |
| CTE005 | Mixed* | IA | 3 | 30% | No | Neg | SLN (3) | No | 10 | VRT + CHT | 19 | NED | / | / |
| CTE037 | CS | IA | 3 | 36% | No | Neg | SLN (3) | No | 16 | VRT + CHT | 29 | NED | / | / |
| CTE025 | Serous | IA | 3 | 42% | No | Neg | SLN (2) | No | 13 | VRT + CHT | 36 | NED | / | / |
| CTE003 | Serous | IIIA | 3 | 100% | Yes | Neg | SLN (11) | Yes** | 26 | CHT + EBRT + VRT | 32 | AWD | 21 (R) | Lung |
| CTE024 | CS | IIIC1 | 3 | 95% | Yes | Pos | SLN + R LND (2+5) | No | 25 | CHT + EBRT + VRT | 36 | DOD | 18 (R) | Lung; Peritoneum; Pelvic, Para-aortic & Supraclavicular Nodes |
| CTE029 | Serous | IIIC1 | 3 | 95% | Yes | Pos | SLN (3) | No | 31 | CHT | 4 | DOD | 3 (PD) | Bone; Liver |
| CTE016 | Endom | IIIC2 | 1 | 72% | Yes | Pos | SLN + LND (3+34) | No | 94 | CHT + EBRT + VRT | 38 | NED | / | / |
| CTE033 | Serous | IIIC2 | 3 | 0% | No | Pos | LND (44) | No | 35 | CHT + EBRT + VRT | 32 | NED | / | / |
| CTE031 | Serous | IVB | 3 | 21% | No | Neg | SLN (3) | Yes | 19 | CHT | 29 | DOD | 13 (R) | Peritoneum; Omentum; Pelvic & Para-aortic nodes |
* Mixed histology: serous and endometrioid
** Uterine serosa. Abbreviations: AWD, alive with disease; CHT, chemotherapy; CS, carcinosarcoma; DOD, dead of disease; EBRT, external beam radiation therapy; Endom, endometrioid; LN, lymph node; LND, lymphadenectomy (number of nodes is how many lymph nodes were taken); NED, no evidence of disease; Neg, negative; Pos, positive; SLN, sentinel lymph node (number of nodes for SLN is how many SLN were taken); PD, progression of disease; VRT, vaginal brachytherapy.